Sotera Health (NASDAQ:SHC) Posts Earnings Results, Misses Estimates By $0.01 EPS

Sotera Health (NASDAQ:SHCGet Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01), Briefing.com reports. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The company had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. During the same period last year, the company earned $0.18 earnings per share. Sotera Health’s revenue for the quarter was up 8.5% compared to the same quarter last year. Sotera Health updated its FY 2024 guidance to 0.670-0.750 EPS and its FY24 guidance to $0.67-0.75 EPS.

Sotera Health Stock Performance

Shares of SHC stock traded up $0.39 during trading on Wednesday, reaching $15.81. The company had a trading volume of 884,591 shares, compared to its average volume of 1,304,161. The firm’s 50 day simple moving average is $15.94 and its two-hundred day simple moving average is $13.67. Sotera Health has a one year low of $10.71 and a one year high of $17.44. The company has a debt-to-equity ratio of 5.46, a current ratio of 2.93 and a quick ratio of 2.59. The company has a market capitalization of $4.48 billion, a PE ratio of 112.93 and a beta of 2.08.

Insiders Place Their Bets

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 55.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Citigroup lifted their price objective on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Finally, Barclays boosted their price target on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Sotera Health currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Get Our Latest Stock Analysis on SHC

Sotera Health Company Profile

(Get Free Report)

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

See Also

Earnings History for Sotera Health (NASDAQ:SHC)

Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.